Trial Profile
A phase I trial of vaccination with autologous, lethally irradiated tumor cells engineered by adenoviral mediated gene transfer to secrete granulocyte-macrophage colony stimulating factor in pediatric and adult patients
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 03 Nov 2021
Price :
$35
*
At a glance
- Drugs Tumour cell vaccine-GVAX (Primary)
- Indications Alveolar soft part sarcoma; Clear cell sarcoma; Malignant melanoma; Renal cell carcinoma
- Focus Adverse reactions
- 02 Mar 2021 Status changed from active, no longer recruiting to completed.
- 26 Jan 2021 Planned End Date changed from 1 Dec 2020 to 1 Dec 2021.
- 06 Jul 2020 Planned End Date changed from 1 Jun 2020 to 1 Dec 2020.